drugset / Trial / NCT01816321

Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial

NCT01816321 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

In combination with the existing literature, previous work indicates that 1) women with poor ovarian response fulfilling the "Bologna criteria" have very low pregnancy rates, irrespective of age 2) current treatment protocols demonstrate ongoing pregnancy rates that do not exceed 8.5% and 3) corifollitropin alfa followed by hpHMG might increase ongoing pregnancy rates in young patients (\<40years old) fulfilling the criteria. These findings provide a strong rationale for a definitive large RCT. The COMPORT study will provide conclusive evidence regarding the superiority or not of this novel protocol with corifollitropin alfa followed by hpHMG for the treatment of young poor ovarian responders fulfilling the Bologna criteria.

Timeline

Start
2013-03
Primary completion
2016-05
Completion
2016-05

Outcome

Missed primary endpoint

paper Corifollitropin alfa followed by hp-HMG does not increase ongoing pregnancy rates compared with rFSH in young poor responders PMID 29040589 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 150 ug —
Subject HP-hMG Protein / enzyme biologic 300 iu —
Comparator recombinant FSH Protein / enzyme biologic 300 iu —
Background Ganirelix Protein / enzyme biologic 0.25 mg —